在线自适应放疗可能降低高危前列腺癌治疗的毒性
本研究纳入20例接受前列腺78 Gy和 elective 盆腔淋巴结56 Gy的高危前列腺癌患者,比较MR引导在线自适应放疗(MRgART)与标准放疗的正常组织并发症概率(NTCP)。MRgART使膀胱壁、直肠和腹膜腔剂量显著降低,中位尿失禁风险降低2.8%、排尿疼痛风险降低2.8%、急性胃肠道毒性风险降低17.4%。
要点
- MRgART相比标准放疗显著降低膀胱壁、直肠和腹膜腔剂量。
- MRgART使中位尿失禁和排尿疼痛风险各降低2.8%,急性胃肠道毒性风险降低17.4%。
- 所有评估的危及器官累积剂量在MRgART计划下等于或优于标准放疗。
核心结论
- 在线自适应放疗可能通过缩小PTV margins降低高危前列腺癌患者危及器官剂量,并可能转化为急性和晚期不良反应风险的显著降低。
研究设计与样本
- 研究纳入20例接受前列腺78 Gy和 elective 盆腔淋巴结56 Gy的患者,采用VMAT计划生成标准临床PTV margins。
- 除计划MRI外,患者在治疗期间接受三次MRI扫描以模拟MRgART,并为每位患者创建基于MRgART PTV margins的参考计划,适配后续每次MRI。
主要发现
- MRgART相比标准放疗在膀胱壁、直肠和腹膜腔产生统计学显著更低的剂量。
- MRgART使中位尿失禁风险降低ΔNTCP 2.8%、排尿疼痛风险降低ΔNTCP 2.8%、急性胃肠道毒性风险降低ΔNTCP 17.4%。
- 所有评估的危及器官平均群体累积剂量在MRgART计划下等于或优于标准放疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: With daily, MR-guided online adapted radiotherapy (MRgART) it may be possible to reduce the PTV in pelvic RT. This study investigated the potential reduction in normal tissue complication probability (NTCP) of MRgART compared to standard radiotherapy for high-risk prostate cancer. MATERIALS AND METHODS: Twenty patients treated with 78 Gy to the prostate and 56 Gy to elective pelvic lymph nodes were included. VMAT plans were generated with standard clinical PTV margins. Additionally to the planning MR, patients had three MRI scans during treatment to simulate an MRgART. A reference plan with PTV margins determined for MRgART was created per patient and adapted to each of the following MRs. Adapted plans were warped to the planning MR for dose accumulation. The standard plan was rigidly registered to each adaptation MR before it was warped to the planning MR for dose accumulation. Dosimetric impact was compared by DVH analysis and potential clinical effects were assessed by NTCP modeling. RESULTS: MRgART yielded statistically significant lower doses for the bladder wall, rectum and peritoneal cavity, compared to the standard RT, which translated into reduced median risks of urine incontinence (ΔNTCP 2.8%), urine voiding pain (ΔNTCP 2.8%) and acute gastrointestinal toxicity (ΔNTCP 17.4%). Mean population accumulated doses were as good or better for all investigated OAR when planned for MRgART as standard RT. CONCLUSION: Online adapted radiotherapy may reduce the dose to organs at risk in high-risk prostate cancer patients, due to reduced PTV margins. This potentially translates to significant reductions in the risks of acute and late adverse effects.
引用
- Christiansen RL, Dysager L, Hansen CR, et al. Online adaptive radiotherapy potentially reduces toxicity for high-risk prostate cancer treatment. Radiother Oncol. 2021. PMID: 34923034. doi:10.1016/j.radonc.2021.12.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。